In the last 18 months PTX via SYC and Bec have put OmniCAR at...

In the last 18 months PTX via SYC and Bec have put OmniCAR at the forefront of Car-T and positioned with TF and MDA to ensure both lower cost of production long term and highest potential for efficacy approval in the forthcoming trials of OmniCAR. Without these 2 attributes and the third one safety - which is a given, such a platform would have difficulty remaining in the top tier for long.
Once the first anticipated good OmniCAR readouts are seen next year then the company will be on a fast track to become the obvious contender for the shovels to the new gold rush in Oncology with help from CellPryme.
While PTX remains the only company with a covalent bond and ticks all the other boxes (not just some) then it will remain in front of the competition to reach the FDA leaders expectation of having a platform that can handle all cell types and binders ASAP.
Venture capitalists are in the same position - waiting to find the company that they will invest in that can treat a large range of solid cancers. Neither are interested in individual binders or specialized delivery systems. Everyone is looking for the ultimate platform that can be used to help cure many/most cancers cheaply and avoid the dangerous relative ineffective current methods and OmniCAR is currently the best and most versatile.

I myself purchased years ago and expected then that we would be selling PTX 200 or 100 about now. That was my imagination working, not what the company was advising and yes they were not advising that it could take 7 years. (3 to go with PTX 100) and many CR's.
Then OmniCAR came along. Again, we are not being advised when it may be approved for it has hurdles to pass with the first and major hurdle being the early readouts next year. Pass that hurdle and it will be game on for SP growth regardless of the necessary CR to complete the trials/gain approval.

I cannot agree or see how you consider OmniCAR is on the back burner, nor stealth mode was a fizzer. To protect IP and conform to exchange rules, companies must control information flow by being secretive = stealth mode. I assume you expected a large SP jump that didn't occur.
Similarly, PTX 100 and 200 both have high potential but PTX 100 at present has far higher economic potential due to strong competition in the AML area including our own OmniCAR variant targeting AML.

I can only assume you are disappointed and possibly sold at a loss for you did hold PTX shares early this year.

I hope you can buy back in soon at these ridiculous prices for most others can see the potential whereas the 'me-too' Car -T competition has only believers and traders left.
I see you hold IMU and watch CHM and PTX so assume you are a trader where I take positions and hold long term unless the fundamentals change sufficiently that may allow the wheels to fall off OR there is an alternative with greater growth potential in this portfolio category.

Where I look at the fundamentals I expect you follow sentiment/SP movements. Where I look for long term potential I expect you look for quick 20, 50 or 100% moves and possibly short for the same result. So we obviously disagree due to differences in investment perspectives.

So I'm sorry I cannot detail when or what will turn the SP up but know it will start to occur well within the 18 months just as many competitors in the Car-T space will fail or have to merge for their work targets only a binder or specialist delivery system for a specific cancer. This is the incrementalism of drug research which is not a broad platform which can control all binders, us all cell types, treat many cancers and have the safety to use multiple binders and even switch them.
This natural selection and elimination of most competition is part of the current overall Car-T SP collapse.
Once the FDA shows interest in OmniCAR to the point of abbreviating the approval process then a lot of Car-T companies will have only their unique binders to sell and only in rare situations will specialized delivery systems be required.
Competition will not go away. There are many aspects need improvement and patents have short lives. SYC has said this is just the beginning. We know that macrophages are in the race as are other cell types other than T cells and for cost reasons there is a strong focus on using off the shelf healthy cells rather than host T cells currently. Fortunately, OmniCAR can handle the lot and undoubtedly will be a part of this new paradigm and highly likely be the initiator of it.

SYC has shared his opinion/expectation of PTX becoming a one stop shop for OmniCAR, all approved binders and our CellPryme improvements to cell production where we can profit from a part of many/most treatments in the near future - where others will profit from specific binders until patents run out, be part of the cell production (TS), others have the infusion rooms and doctors have their take. Hospitals may have lower usage but patients should see significant benefits and live longer. Far more cures are expected for most cancers.
This means that chemo drug companies, radiology facilities and surgeons will have less work.
SYC has already said that dividends are unlikely for the profits could be used for further research on oncology and other fields. I.e. become a significant growth company within the health field with time.
I have not found a company with greater growth prospects. My best so far was a 15 bagger. PTX has to have 50 to 100 bag potential from current to 20 cants SP over years, especially when the expected dual US listing occurs.If it works on other chronic/deadly diseases as well then it could have unicorn potential.

A few shareholders are also looking for a quick sale to any takeover offer IMO which I doubt will occur until OmniCAR is well in the a trial and showing its potential.
Penn gave PTX sole licensing rights for its half of OmniCAR and IMO this was to keep the major drug companies out as well as the riff-Raff to ensure this new treatment system would not be restricted to ensure current drug profits or exorbitant new ones.
I expect Penn was also interested in an Australian company with far lower costs of research to keep it low key until the kinks had been ironed out - and be out of the US spotlight for information leakage.

All the best with IMU and your other holdings. I am very happy with holding PTX in this critical time when our new board members pass on their expertise to guide the next phases with collaborations and post approval company direction/structure.